KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Taxes: 2014-2022

Historic Current Taxes for Pacira BioSciences (PCRX) over the last 7 years, with Jun 2022 value amounting to $11,000.

  • Pacira BioSciences' Current Taxes was N/A to $11,000 in Q2 2022 from the same period last year, while for Jun 2022 it was $11,000, marking a year-over-year change of. This contributed to the annual value of $429,000 for FY2021, which is 276.32% up from last year.
  • As of Q2 2022, Pacira BioSciences' Current Taxes stood at $11,000, which was down 98.73% from $863,000 recorded in Q1 2022.
  • In the past 5 years, Pacira BioSciences' Current Taxes ranged from a high of $1.7 million in Q1 2020 and a low of $11,000 during Q2 2022.
  • Moreover, its 3-year median value for Current Taxes was $575,000 (2021), whereas its average is $735,625.
  • Examining YoY changes over the last 5 years, Pacira BioSciences' Current Taxes showed a top increase of 1,970.51% in 2020 and a maximum decrease of 91.45% in 2020.
  • Quarterly analysis of 5 years shows Pacira BioSciences' Current Taxes stood at $90,000 in 2018, then skyrocketed by 1,381.11% to $1.3 million in 2019, then crashed by 91.45% to $114,000 in 2020, then spiked by 276.32% to $429,000 in 2021, then grew by 19.69% to $11,000 in 2022.
  • Its Current Taxes was $11,000 in Q2 2022, compared to $863,000 in Q1 2022 and $429,000 in Q4 2021.